EHA 2023 | Using MRD to guide treatment decisions during SCT in multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the use of measurable residual disease (MRD) to guide treatment decisions in patients with multiple myeloma. Dr Costa explains that patients who remain MRD-positive following triplet or quadruplet induction therapy have poorer outcomes and may therefore benefit from continuing or escalating therapy. In contrast, patients who are not ultra-high-risk and maintain MRD-negativity after stem cell transplantation (SCT) have better outcomes and may not need additional therapy. Finally, Dr Costa comments on the use of MRD to assess the duration of maintenance therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.
